The primary goal of this meeting will be to explore collaborative partnerships in the development of combination therapies for Alzheimer's disease (AD). The Food and Drug Administration (FDA)'s draft guidance on the development of multiple therapies in combination for AD treatment will also be discussed.
More information about the meeting may be found at www.agingresearch.org/content/calendar/detail/19964 
Email: dinabeau [ at ] aol [dot] com
|file_ACT_AD_Fall_2012_Agenda.pdf ||149.5 KB|